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The induction of donor specific transplantation toler-
ance remains the ultimate goal for clinical organ grafting,
as it would avoid the problems of toxicity, susceptibility to
infections and tumors that arise from the current need to
give long-term, nonspecific, immunosuppressive drugs. It
is now more than 50 years since it was first demonstrated
that such tolerance could be induced in neonatal rodents,
or lethally irradiated adults, by inducing sufficient donor
chimerism to maintain tolerance by clonal deletion of al-
loreactive T cells in the thymus. Many different attempts
to extend such approaches to the clinic have generally
not proven to be viable.
More recently, it was found that monoclonal antibodies
against various T-cell antigens, particularly combinations
of CD4, CD40L, and CD8, were able to block rejection
of allografts in adult rodents [1]. More important, such
recipients eventually became specifically tolerant of the
donor alloantigens, able to accept fresh donor-type grafts,
but reject those from a third party. This induction of tol-
erance did not require any depletion or overt clonal dele-
tion of donor-reactive T cells, and was independent of the
thymus. Tolerance could be induced directly to skin [1] or
vascularized heart grafts [2] across a full major histocom-
patibility complex (MHC) plus minor antigens mismatch.
In vitro there were no differences in T-cell responses from
tolerant or rejecting mice, but tolerance in vivo was found
to be dependent on CD4+ regulatory T cells [3].
A major question now is whether these regulatory T
cells found in transplantation tolerance are related to the
“natural” population of CD4+ CD25+ regulatory T cells
[4], or to interleukin (IL)-10 producing Tr1 cells, both
of which have been described in various models of au-
toimmune disease. Both types of regulatory T cells were
able to suppress allograft rejection after adoptive transfer
into lymphopenic recipients, but neither is able to reca-
pitulate the power and exquisite specificity demonstrated
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by the phenomena of linked suppression and infectious
tolerance as seen in intact, tolerant mice [5]. Gene ex-
pression analyses suggest that CD4+ CD25+ and Tr1
cells share certain molecular markers, such as CTLA-
4, glucocorticoid-induced tumor necrosis factor receptor
(TNFR) (GITR), OX40, and ppENK [6], but as yet there
are still no clear molecular markers for the tolerant state
in vivo.
In order to fully apply such approaches to the clinic we
need appropriate combinations of humanized, truly non-
depleting, monoclonal antibodies, used at sufficient doses
to maintain T-cell blockade over a number of days. We
also need good surrogate markers for the tolerant state, so
that the antibody, or other compatible immunosuppres-
sive drugs, can be safely withdrawn. In the meantime, we
may be able to approach clinical tolerance by identify-
ing immunosuppressive combinations of drugs and mon-
oclonal antibodies [7] that permit the immune system to
develop tolerance for itself, thereby reducing the long-
term drug burden for the patient.
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